89302-81-8

Basic information

• Product Name: Phosphonium, [(3-fluorophenyl)methyl]triphenyl-, bromide
• Synonyms: 3-fluorobenzyltriphenylphosphinium bromide;m-fluorobenzyltriphenylphosphonium bromide;T0400-2411
• CAS NO: 89302-81-8
• Molecular Formula: C25H21FP.Br
• Molecular Weight: 451.318
• Mol File: 89302-81-8.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Phosphonium, [(3-fluorophenyl)methyl]triphenyl-, bromide(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonium, [(3-fluorophenyl)methyl]triphenyl-, bromide(89302-81-8)
• EPA Substance Registry System: Phosphonium, [(3-fluorophenyl)methyl]triphenyl-, bromide(89302-81-8)

Safety Data

• Hazardous Substances Data: 89302-81-8(Hazardous Substances Data)

Upstream product

• 603-35-0 triphenylphosphine 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 456-47-3 3-fluoro-benzenemethanol 

Downstream Products

• 193203-93-9 1-benzyl-4-(3-fluorobenzylidene)piperidine 
• 15332-20-4 3,3'-difluorostilbene 
• 928626-29-3 2-[2-(3-fluorophenyl)vinyl]naphthalene 
• 1253931-23-5 (3-fluorobenzyltriphenylphosphinium)bis(maleonitriledithiolate)nickelate 
• 1429328-25-5 (Z)-2-(3-fluorostyryl)-3,4-dihydro-2H-pyran 
• 1429328-51-7 (Z)-2-(3-fluorostyryl)-2H-pyran-4(3H)-one 
• 1429328-65-3 (E)-5-(3-fluorostyryl)dihydrofuran-2(3H)-one 
• 1429328-66-4 (Z)-5-(3-fluorostyryl)dihydrofuran-2(3H)-one 
• 148492-14-2 4-(3-fluorophenethyl)piperidine 
• 221639-90-3 [(3-fluorophenyl)methylene]triphenylphosphorane 

Relevant articles and documents

Substituted dienes prepared from betulinic acid – Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters

A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.

One-Step Synthesis of Substituted Benzofurans from ortho- Alkenylphenols via Palladium-Catalyzed C=H Functionalization

A dehydrogenative oxygenation of C(sp2)=H bonds with intramolecular phenolic hydroxy groups has been developed, which provides a straightforward and concise access to structurally diversely benzofurans from ortho-alkenylphenols. The reaction is catalyzed by palladium on carbon (Pd/C) without any oxidants and sacrificing hydrogen acceptors.

TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against me